Phenolic glycolipids (PGLs) are non-covalently bound components of the outer membrane of many clinically relevant mycobacterial pathogens, and play important roles in pathogen biology. We report a mutational analysis that conclusively demonstrates that the conserved acyltransferase-encoding gene papA5 is essential for PGL production. In addition, we provide an in vitro acyltransferase activity analysis that establishes proof of principle for the competency of PapA5 to utilize diol-containing polyketide compounds of mycobacterial origin as acyl-acceptor substrates. Overall, the results reported herein are in line with a model in which PapA5 catalyses the acylation of diol-containing polyketides to form PGLs. These studies advance our understanding of the biosynthesis of an important group of mycobacterial glycolipids and suggest that PapA5 might be an attractive target for exploring the development of antivirulence drugs.
INTRODUCTION
The mycobacterial cell envelope contains a distinctive array of complex free lipids and glycolipids associated with the mycolic acid layer of the cell wall (Brennan & Nikaido, 1995; Crick et al., 2008; Onwueme et al., 2005a) . These lipids and glycolipids are thought to be located in the membrane outer leaflet that partners with the mycolic acid-based membrane inner leaflet to form the asymmetric lipid bilayer that constitutes the characteristic mycobacterial outer membrane. Among the free lipids found in the outer membrane of Mycobacterium leprae, various strains of Mycobacterium tuberculosis and several opportunistic mycobacterial human pathogens are two structurally related groups of diesters, both composed of glycolcontaining long-chain aliphatic polyketides and polyketide synthase-derived methyl-branched fatty acids (Onwueme et al., 2005a) . One of these groups of unusual lipid diesters is represented by phenolphthiocerol dimycocerosates, which are glycosylated compounds generally known as phenolic glycolipids (PGLs) . The other group is represented by phthiocerol dimycocerosates (PDIMs), which lack the aromatic ring and glycosidic moieties characteristic of PGLs (Fig. 1 ).
An overwhelming body of evidence has accumulated that demonstrates that PGLs and PDIMs play important roles in host-pathogen interaction and/or virulence in various mycobacterial pathogens (Alibaud et al., 2011; AstarieDequeker et al., 2009; Brodin et al., 2010; Camacho et al., 1999; Collins et al., 2005; Cox et al., 1999; Dhungel et al., 2008; Murry et al., 2009; Ng et al., 2000; Rambukkana et al., 2002; Reed et al., 2004; Robinson et al., 2008; Ruley et al., 2004; Sinsimer et al., 2008; Tsenova et al., 2005) . Moreover, production of these compounds has been shown to correlate with decreased antimicrobial drug susceptibility (Alibaud et al., 2011; Chavadi et al., 2011b) . PGL production has also been suggested as a trait that predisposes M. tuberculosis strains of the W-Beijing family to their characteristic epidemic spread and increased likelihood of developing drug resistance (Reed et al., 2007) . Thus, dissecting the molecular logic of PGL and PDIM biosynthesis not only will expand our general understanding of cell wall biosynthesis in mycobacteria of clinical significance, but also may reveal potential avenues for exploring the development of alternative therapeutics against selected mycobacterial infections (Ferreras et al., 2008; Quadri, 2007) . These views have directed our previous studies of the biosynthesis of PGLs and PDIMs Chavadi et al., 2011b; Ferreras et al., 2008; He et al., 2009; Onwueme et al., 2004 Onwueme et al., , 2005a , which include the development of the first PGL biosynthesis inhibitor (Ferreras et al., 2008) . This inhibitor drastically reduces PGL production in several Mycobacterium species (Ferreras et al., 2008 ) using a mechanistic principle analogous to that of the first reported inhibitor of mycobacterial siderophore (iron chelator) production (Ferreras et al., 2005; Quadri, 2007) . Despite significant progress made towards understanding the partially overlapping biosynthetic routes of PGLs and PDIMs (Onwueme et al., 2005a) , many aspects of these pathways remain unclear. One such aspect is whether the conserved gene papA5 is required for PGL production. An orthologue of papA5 is clustered with genes that have confirmed or suspected involvement in PGL and/or PDIM production in each PDIM/PGL producer for which the genome has been analysed (Onwueme et al., 2005a) . We have previously established that papA5 is required for PDIM production, demonstrated that PapA5 has acyltransferase activity and reported the crystal structure of PapA5 from M. tuberculosis Onwueme et al., 2004) . The earlier mutational work involved the characterization of a papA5 knockout engineered in the Erdman strain of M. tuberculosis, a strain that is PGL-deficient due to a natural mutation in a polyketide synthase gene required for PGL synthesis (Constant et al., 2002; He et al., 2009) . The study of PapA5 was conducted using non-physiological aliphatic alcohols as surrogate substrates. Thus, it remains unknown whether papA5 is required for PGL production, and demonstration of the ability of PapA5 to utilize mycobacterial alcohols as acyl acceptor substrates is lacking.
In this study, we report a mutational analysis that conclusively establishes that papA5 is required for production of PGLs in the opportunistic human pathogen Mycobacterium marinum. We also present in vitro biochemical evidence to demonstrate that PapA5 has the capacity to utilize mycobacterial glycosyl-phenolphthiocerols as acyl acceptor substrates. Overall, the studies reported herein advance our understanding of the biosynthesis of an important group of mycobacterial cell wall glycolipids. Bacterial culturing and recombinant DNA manipulations. M. marinum (strain M; ATCC BAA-535) was cultured at 30 uC in Middlebrook 7H9 medium (Difco) supplemented with 10 % ADN (5 % BSA, 2 % glucose, 0.85 % NaCl) (Difco) and 0.05 % Tween-80 (supplemented 7H9) or Middlebrook 7H11 (Difco) supplemented with ADN (supplemented 7H11) (Chavadi et al., 2011b) . Escherichia coli DH5a (Invitrogen) was cultured in Luria-Bertani media under standard conditions (Sambrook et al., 1989) . When required, kanamycin (30 mg ml 21 ), hygromycin (50 mg ml 21 ), sucrose (2 %) and/or X-Gal (70 mg ml
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) were added to the media. General recombinant DNA manipulations were carried out by standard methods and using E. coli DH5a as the primary cloning host (Sambrook et al., 1989) . PCR-generated DNA fragments used in plasmid constructions were sequenced to verify fidelity. Genomic DNA isolation from and plasmid electroporation into mycobacteria were carried out as reported elsewhere (Parish & Stoker, 1998) . The plasmids and oligonucleotides used in this study are shown in Table 1 . Construction of M. marinum DpapA5. The mutant was engineered using the p2NIL/pGOAL19-based flexible cassette method (Parish & Stoker, 2000) as reported previously (Chavadi et al., 2011a, b; Ferreras et al., 2008; Onwueme et al., 2004) . A suicide delivery vector (p2NIL-GOALc-DpapA5c, see below) carrying a papA5 (MMAR_1768) deletion cassette (DpapA5c) was used to generate M. marinum DpapA5. Electroporation of p2NIL-GOALc-DpapA5c into M. marinum and selection of potential single-and double-crossover mutants were conducted as previously reported (Chavadi et al., 2011b) . The papA5 deletion in potential double-crossover mutants was screened for and confirmed by PCR using two independent primer pairs (papA5OF and papA5OR, papA5F and papA5R).
Construction of p2NIL-GOALc-DpapA5c. The construction of the plasmid is outlined in Supplementary Fig. S1 (available with the online version of this paper). The deletion cassette DpapA5c was generated using splicing by overlap extension (SOE) PCR (Horton et al., 1989) . DpapA5c contained a 59 arm (485 bp5479 bp segment upstream of papA5+papA5 first two codons) and a 39 arm (554 bp5papA5 last two codons+stop codon+545 bp segment downstream of papA5). Each arm was PCR-generated from genomic DNA. Primer pair papA5OF and papA5IR and primer pair papA5IF and papA5OR were used to generate the 59 and 39 arms, respectively. The arms were then used as a template for PCR with primers papA5OF and papA5OR to fuse the arms and generate DpapA5c (1039 bp). The PCR-generated DpapA5c was cloned into pCR2.1Topo (Invitrogen). DpapA5c was subsequently excised from the pCR2.1Topo construct using HindIII and PacI, and the excerpt was ligated to plasmid p2NIL (Parish & Stoker, 2000) linearized by HindIII/PacI digestion. The resulting p2NIL-DpapA5c plasmid and plasmid pGOAL19 (Parish & Stoker, 2000) were digested with PacI, and the PacI cassette (GOALc, 7939 bp) of pGOAL19 was ligated to the linearized p2NIL-DpapA5c backbone to create p2NIL-GOALc-
DpapA5c.
Construction of pCP0-papA5mm. A DNA fragment (1275 bp) encompassing papA5 of M. marinum (papA5mm) and its predicted ribosome-binding site (RBS) was PCR-generated from genomic DNA using primer pair papA5F (starts and ends 20 nt upstream and 1 nt downstream, respectively, of the start codon) and papA5R (starts and ends 11 nt upstream and 10 nt downstream, respectively, of the stop codon). The PCR product was cloned into pCR2.1Topo. The RBS-papA5mm insert was recovered from the pCR2.1Topo construct as a PstI-HindIII fragment and the excerpt was subcloned into the expression vector pCP0 linearized by PstI/HindIII digestion. The cloned papA5mm was placed under the control of the hsp60 promoter of pCP0 for expression in mycobacteria.
Analysis of PGLs and PDIMs. Five-day-old mycobacterial cultures were diluted to OD 595 0.6 in supplemented 7H9 and loaded into 12-well plates (1 ml per well). [
14 C]Propionate was added to each well at 0.2 mCi ml 21 (7.4 MBq ml 21 ) and the plates were incubated at 30 uC with rotary agitation (170 r.p.m.) for 24 h. After incubation, the OD 595 of the cultures was measured in a DTX Plate Reader (Beckman Coulter), and the cells were harvested for apolar lipid fraction extraction with a biphasic mixture of methanolic saline and petroleum ether, as reported previously (Chavadi et al., 2011b; Ferreras et al., 2008) . The lipid extracts were subjected to radio-TLC for analysis of 14 C-labelled PGLs (using CHCl 3 /CH 3 OH, 95 : 5) and PDIMs (using petroleum ether/diethyl ether, 9 : 1) as described previously (Ferreras et al., 2008) . Developed TLC plates were exposed to phosphor screens, which were scanned using a Cyclone Plus Storage Phosphor System (PerkinElmer Life and Analytical Sciences).
Purification of GPPOLs. PGLs were purified from M. lepraeinfected Armadillo tissues. Briefly, homogenized M. leprae infected liver (10 g) supernatants were lyophilized and extracted with CHCl 3 / CH 3 OH (2 : 1) at 50 uC for 18 h. The homogenate was centrifuged and the organic layer (lower phase) was collected. This organic layer served as the main source of PGLs. The organic layer was washed with water, concentrated and extracted with diethyl ether. The ethersoluble dried lipids were resuspended in CHCl 3 , applied to a silica gel G60 column (2.5660 cm), and successively eluted from the column with CHCl 3 containing increasing concentrations of CH 3 OH (0-20 %). Most of the PGL eluted with CHCl 3 containing 2 % and 5 % CH 3 OH. The pure PGL preparation was obtained after normal-phase HPLC of the silica gel-purified material. Fractions off HPLC were screened for PGLs by TLC on aluminium-backed silica gel G plates (Merck) developed with CHCl 3 /CH 3 OH/H 2 O (90 : 10 : 1). The identity of the purified PGLs was confirmed using fast atom bombardment MS (results not shown) as reported elsewhere (Brennan et al., 1994) . The purified PGLs were deacylated by procedures based on those described elsewhere (Hunter & Brennan, 1981) . PGLs were hydrolysed with 10 % NaOH in toluene/CH 3 OH GPPOL palmitoylation assay. Reactions for assessment of PapA5-dependent GPPOL palmitoylation contained 18 mM [ 14 C]palmitoylCoA, 450 mM purified GPPOLs, 10 mM enzyme, 100 mM NaCl and 75 mM MES buffer (pH 6.2), and were incubated at 37 uC for 24 h. Negative control reactions contained the inactive PapA5 variant PapH 124 A or an equivalent volume of enzyme buffer (100 mM NaCl, 75 mM MES, pH 6.2). After incubation, the reactions were quenched by addition of CHCl 3 /toluene/CH 3 OH (6 : 4 : 2) followed by vigorous mixing. The organic layers were recovered and analysed by TLC on aluminium-backed, 250 mm thick, silica gel plates (EM Science or Whatman). TLC plates were developed with CHCl 3 /CH 3 OH/H 2 O (90 : 10 : 1) and exposed to phosphor screens, and reaction products were quantified with a Storm 860 Imaging System (Molecular Dynamics). For dose-response experiments, reactions contained GPPOLs at the indicated concentrations, 18 mM [ 14 C]palmitoyl-CoA, 0.5 mM PapA5, 100 mM NaCl and 75 mM MES, pH 6.5. After incubation (37 uC, 3 h), the reactions were quenched, extracted and analysed by radio-TLC as noted above. Dose-response data were fitted to the equation v5V max /[1+K m / S+S/K i ] to calculate apparent kinetic parameters and an apparent K i value. Data were plotted and analysed using KaleidoGraph software. Recombinant PapA5 and PapH 124 A were purified as reported previously Onwueme et al., 2004) .
MS analysis of GPPOL palmitoylation products. GPPOL palmitoylation reactions for MS analysis of reaction products contained unlabelled palmitoyl-CoA (360 mM), GPPOL (360 mM) and enzyme (90 mM), or an equivalent volume of the enzyme buffer described above in negative control reactions. Reactions were incubated at 37 uC for 24 h and then quenched and extracted as above. The organic extracts were analysed by MALDI-TOF MS. The analyte was mixed with matrix solution (10 mg 2,5-dihydroxybenzoic acid ml 21 in CHCl 3 /CH 3 OH, 1 : 1) and the resulting mix was applied onto the MALDI sample plate. Spectra were acquired on a Voyager-DE PRO 6320 instrument (Applied Biosystems). The instrument was calibrated using bradykinin fragment 1-7 (monoistopic mass 757.4), human angiotensin II (monoisotopic mass 1046.5) and a synthetic peptide P 14 R (monoisotopic mass 1533.8). The distributions in the spectra of the reactions were calibrated based on the main GPPOL species found in the purified substrate {observed [(M+Na 
RESULTS AND DISCUSSION
Construction of a papA5 deletion mutant of M. marinum
We have previously demonstrated that papA5 is required for production of PDIMs . In this study, we sought to determine whether papA5 was required for production of PGLs. Towards this end, we utilized M. marinum as a prototype representative of mycobacteria that produce both PGLs and PDIMs. M. marinum is an opportunistic human pathogen closely related to M. tuberculosis (Stinear et al., 2008) and offers superior experimental tractability compared with other PGLproducing mycobacteria.
We engineered strain M. marinum DpapA5, an unmarked, in-frame papA5 deletion mutant of M. marinum, and examined the capacity of this strain to produce PGLs and PDIMs as described below. The deletion was engineered using the papA5 deletion cassette-delivery suicide vector p2NIL-GOALc-DpapA5c (Fig. 2a) in a homologous recombination-and counterselection-based approach that replaced papA5 by a 4-codon remnant engineered into the papA5 deletion cassette of p2NIL-GOALc-DpapA5c. The deletion in M. marinum DpapA5 encompassed 412 central codons of papA5, and it was verified by PCR using two independent primer pairs, each producing diagnostic amplicons of different sizes depending on whether the genomic DNA used as template was wild-type (WT) or carried the papA5 deletion (Fig. 2b) . The successful engineering of M. marinum DpapA5 set the stage for probing the involvement of papA5 in PGL production.
papA5 is required for production of both PGLs and PDIMs
We investigated the effect of the papA5 deletion in M. marinum DpapA5 on PGL and PDIM production using published radio-TLC methods (see Methods). In addition, a control strain for genetic complementation analysis was constructed (M. marinum DpapA5+pCP0-papA5mm, a plasmid expressing papA5mm), and the ability of this strain and that of M. marinum WT controls to produce PGLs and PDIMs was examined. We carried out metabolic labelling of mycobacterial cultures of these strains by feeding [ 14 C]propionate to obtain labelled PGLs and PDIMs for radio-TLC analysis. Representative results of this radio-TLC analysis are shown in Fig. 3 . The analysis of lipid samples from M. marinum WT and M. marinum WT+pCP0 (empty vector control) revealed the presence of both PGLs and PDIMs, as expected based on previous reports (Ferreras et al., 2008) . More importantly, the analysis of samples from M. marinum DpapA5 and M. marinum DpapA5+pCP0 indicated that deletion of papA5 led not only to PDIM deficiency, a result expected based on the phenotype of M. tuberculosis DpapA5 , but also to PGL deficiency. Introduction of pCP0-papA5mm into M. marinum DpapA5 complemented the mutant. The episomal expression of papA5mm restored PGL and PDIM production in M. marinum DpapA5+ pCP0-papA5mm to levels similar to those seen in M. marinum WT (Fig. 3) . Overall, the results of the mutational analysis conclusively demonstrate that papA5 is required for production of both PGLs and PDIMs in M. marinum.
PapA5 can catalyse acylation of mycobacterial diol-containing aliphatic polyketides in vitro
Using commercially available surrogate substrates we have previously demonstrated the capacity of M. tuberculosis PapA5 to catalyse hydroxyl-ester formation chemistry . In these previous studies, surrogate alcohol and acyl-CoA thioester substrates replaced the suspected mycobacterial diol-containing aliphatic polyketide and multimethyl-branched fatty acyl thioester substrates, respectively, in the proposed esterification reactions catalysed by PapA5 Onwueme et al., 2004 Onwueme et al., , 2005a . Herein, we set out to conduct a first examination of the ability of PapA5 to utilize mycobacterial diol-containing aliphatic polyketides as acyl acceptor substrates. To this end, we purified M. leprae PGL-derived GPPOLs to use as test substrates. M. leprae in infected Armadillo tissue produces PGLs in amounts that facilitate PGL isolation, and subsequent PGL hydrolytic deacylation and GPPOL purification (see Methods). The identity of the purified GPPOL preparation was verified by MS analysis. The mass spectrum of purified GPPOLs revealed the expected ion peak array, with a mass distribution pattern showing the 14 a.m.u. (-CH 2 -unit) periodicity arising from the characteristic carbon chainlength heterogeneity in the phenolphthiocerol component of PGLs (Onwueme et al., 2005a) (Fig. 4c) . The main GPPOL species in the GPPOL preparation had an observed m/z of 1123.79. This m/z value is in agreement with the calculated m/z of 1123.75 for the sodium adduct [(M+Na + )] + of the GPPOL species shown in Fig. 4(d) . The availability of purified GPPOLs set the stage for a first examination of the competency of PapA5 to utilize a mycobacterial acyl acceptor substrate.
We utilized a radio-TLC-based acyltransferase assay to investigate the ability of recombinant M. tuberculosis PapA5 to acylate purified GPPOLs in vitro. Representative results of this analysis are shown in Fig. 4(a, b) . In these experiments, [ 14 C]palmitoyl-CoA was used as both a surrogate acyl donor substrate and a convenient radiotracer for visualization of [ 14 C]palmitoyl-derived ester products by radio-TLC analysis. Palmitoyl-CoA was selected as the acyl donor for these experiments because it is the most effective surrogate acyl donor among nearly 20 commercially available acyl-CoA thioesters tested as substrates of PapA5 (Onwueme et al., 2004) . TLC analysis of reactions with PapA5, purified GPPOLs and [ 14 C]palmitoyl-CoA revealed the formation of two main labelled products (Fig. 4a) . The product with the higher R f is palmitate, which is known to be formed by non-specific hydrolysis of [ 14 C]palmitoyl-CoA under our reaction conditions . The product with the lower R f was formed only in reactions containing both PapA5 and substrates. Formation of the lower R f product was not detected in reactions lacking PapA5 (Fig. 4a) , in reactions without GPPOL , or in reactions with the PapA5 variant PapH 124 A in place of PapA5 (not shown). PapH 124 A has the catalytic residue His-124 replaced by Ala and lacks acyltransferase activity Onwueme et al., 2004) . We reasoned that the lower R f product was emerging from PapA5-catalysed palmitoylation of GPPOL, and indeed MS analysis supported the identity of the product as GPPOL-monopalmitate (see below). Notably, the TLC analysis revealed the presence of two less abundant products flanking the lower R f product (hereafter referred to as GPPOL-monopalmitate). These secondary products are likely to arise from formation of GPPOL-monopalmitates with carbon chain-length heterogeneity in the GPPOL component (Fig. 4c ). This view is in agreement with the results of the MS analysis described below. PapA5-dependent formation of GPPOL-monopalmitate was dependent on the concentration of GPPOLs in the reaction mixture, and an apparent substrate inhibition effect was observed at high levels of GPPOLs in the reaction (Fig. 4b) . Apparent V max , K m and K i values determined from these data were 5610 24 min
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, 103 mM and 496 mM, respectively.
We probed the PapA5-dependent formation of GPPOLpalmitate esters by MS. Comparative analysis of mass spectra obtained from reactions containing PapA5 and the mass spectra of negative control reactions (no enzyme) validated the PapA5-dependent formation of GPPOL-monopalmitate (Fig. 4c) . As expected, the mass spectra of both PapA5-containing and negative control reactions displayed an ion peak array with the mass distribution characteristic of the purified GPPOLs. Most importantly, an ion peak array centred at m/z51361.86 was detected only in reactions containing PapA5. This m/ z value corresponds to the sodium adduct [(M+Na + )] + of the main GPPOL species present in the purified GPPOL preparation plus the addition of 238.07 a.m.u. This mass gain is concordant with the expected acylation of the main GPPOL species with a palmitoyl chain to form GPPOL-monopalmitate (Fig. 4d) . The additional ion peaks in the array had m/z values that matched those predicted for the sodium adducts of monopalmitate esters derived from secondary GPPOL species present in the GPPOL preparation. Formation of polyacylated GPPOLs was not detected by MS. PapA5 is expected to acylate both hydroxyl groups in the diol of the phenolphthiocerol chains during in vivo PGL biosynthesis. The in vitro observed monopalmitoylation is not surprising considering that the use of a non-physiological acyl donor substrate and the lack of potentially relevant factors (protein partners, possibility of membrane association) in the acylation assay might affect the processivity and kinetic parameters of PapA5.
The ability of PapA5 to acylate GPPOLs of different carbon chain length in vitro is in line with the proposed role of this enzyme in the biosynthesis of PGLs with carbon chainlength variability in the phenolphthiocerol moiety. Due to the inability of the PapA5 active site cavity to accommodate the bulky oligosaccharide unit of GPPOL , and since PapA5 acylates alkanol and alkanediol surrogate substrates with a hydrophobic character but not sugars , we propose that the observed palmitoylation is likely to take place at one of the hydroxyl groups of the diol of phenolphthiocerol (Fig. 4d) . Future studies will be required to validate this prediction, which is consistent with the hypothesized physiological acylation target of PapA5.
In conclusion, the results of both the in vivo mutational analysis and the in vitro biochemical studies presented herein are in line with a model in which PapA5 catalyses the acylation of diol-containing aliphatic polyketides with multimethyl branched fatty acids during biosynthesis of PGLs. The enzymic assay developed herein will provide a basis for more advanced studies of PapA5 activity, whereas the availability of M. marinum DpapA5 will facilitate future studies of biosynthetic intermediate accumulation. Overall, our studies advance the understanding of the biosynthesis of an important group of mycobacterial cell wall glycolipids and suggest that PapA5 might be an attractive target for the development of drugs that inhibit the biosynthesis of both PGLs and PDIMs. Such antivirulence drugs might be combined with conventional antimicrobial drugs in the treatment of selected mycobacterial infections.
